Note: Upacicalcet is an investigational product candidate in the United States and subject to regulatory review and approval by the U.S. Food and Drug Administration (FDA).
Oversubscribed Financing Paves Path to NDA Submission and Pre-commercialization Efforts for upacicalcet RESEARCH TRIANGLE PARK, NC – August 20, 2024 – Pathalys Pharma, Inc., a
RESEARCH TRIANGLE PARK, NC — August 13, 2024 – Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney
Pathalys and LaunchTx leverage recently announced collaboration to accelerate enrollment for the upacicalcet development program. Research Triangle Park, North Carolina and Boston, Massachusetts, May 31, 2023 – Pathalys Pharma,
Abingworth, a leading transatlantic life sciences investment firm and part of global investment firm Carlyle (NASDAQ: CG), led financings and was joined by Carlyle, OrbiMed,
RESEARCH TRIANGLE PARK, N.C., June 2, 2022 – Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range…
Research Triangle Park, N.C., April 8, 2022 – Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range